Results 241 to 250 of about 7,636,605 (392)

Should the drug industry work with key opinion leaders? Yes [PDF]

, 2008
Charlie Buckwell
openalex   +1 more source

Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions.
Philipp Klyscz, Carolin Otto, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Christian Meisel, Judith Bellmann‐Strobl, Friedemann Paul, Patrick Schindler   +8 more
wiley   +1 more source

The impact of patent activity on idiosyncratic volatility in U.S. pharmaceutical companies. [PDF]

PLoS One
Atilgan E, Türkmen Ceylan FB, Doruk ÖT, Ertuğrul HM, Barak AY.   +4 more
europepmc   +1 more source

Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. [PDF]

, 2020
Do, Thao P, Giacomini, Kathleen M, Huang, Shiew-Mei, Krauss, Ronald M, Kusuhara, Hiroyuki, Sugiyama, Yuichi, Unadkat, Jashvant D, Yee, Sook Wah   +7 more
core   +2 more sources

NIMH Initiatives to Facilitate Collaborations Among Industry, Academia, and Government for the Discovery and Clinical Testing of Novel Models and Drugs for Psychiatric Disorders [PDF]

, 2008
Linda S. Brady, Lois Winsky, Wayne K. Goodman, Mary Ellen Oliveri, Ellen Stover   +4 more
openalex   +1 more source

Functional Characterization and Pathogenicity Classification of PRRT2 Splice Variants in PRRT2‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Paroxysmal kinesigenic dyskinesia (PKD) is the most common hereditary paroxysmal movement disorder. The PRRT2 gene is the first identified causative gene and accounts for the majority of PKD. In this study, we investigated the pathogenicity of PRRT2 variants in the splice regions. Methods Patients with clinically suspected PKD and no
Jiao‐Jiao Xu, Yu‐Lan Chen, Wan‐Bing Sun, Hong‐Fu Li, Zhi‐Ying Wu, Dian‐Fu Chen   +5 more
wiley   +1 more source

Clarifying the Gateway Hypothesis and Conflict of Interest in Cannabis Research. [PDF]

Neuropsychopharmacol Rep
Shiraishi K.
europepmc   +1 more source

Clinical Trial Design and Consequences for Drug Development for Community‐Acquired Pneumonia: An Industry Perspective [PDF]

, 2008
Glenn Tillotson, Roger Echols
openalex   +1 more source

A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The optimal treatment for neurosarcoidosis myelitis is uncertain. We characterize incident neurosarcoidosis myelitis and assess treatment response by MRI and clinical scales. Methods Incident probable or definite neurosarcoidosis myelitis in adults was retrospectively identified from 13 academic medical centers.
Giovanna S. Manzano, Denis Balaban, Yihan Zhang, Brian Healy, Bart K. Chwalisz, Michael Levy, Nagagopal Venna, Barney J. Stern, Carlos A. Pardo, Paula Barreras, Nicole Bou Rjeily, Eoin P. Flanagan, Vyanka Redenbaugh, Allen J. Aksamit Jr., Spencer Hutto, Max Herman, Sally El Sammak, Elsa C. Rodriguez, Laura Snider, Hannah Rains, Mayra Montalvo, Torge Rempe, Sergi Martinez Ramirez, Lucas Horta, Stacey Clardy, Jennifer Lord, Tracey A. Cho, Lama Abdel Wahed, Joseph R. Berger, Rohini D. Samudralwar, Noellie Rivera Torres, David B. Clifford, Steven Richard Dunham, Masoud Majed, Aram Zabeti, Samuel Marcucci, Yang Mao‐Draayer, Jon Doty, Paunel B. Agyei, Shamik Bhattacharyya   +39 more
wiley   +1 more source